PFIZER INC Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
PFIZER INC (PFE) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of $7.00 million for the 3-month period ending 2018-04-01, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2018-05-10
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2018-04-01 was $7.00M, a 86.54% decline year-over-year.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2017-12-31 was $55.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2017-10-01 was $29.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2017-07-02 was $88.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2017 was $224.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2016 was -$158.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2015 was -$104.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2014 was -$262.00M, a 515.87% decline from fiscal 2013.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 9 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2018-04-01 | $7.00M 10-Q · filed 2018-05-10 | $62.00M derived: sum of 2 quarters · filed 2018-05-10 | $91.00M derived: sum of 3 quarters · filed 2018-05-10 | $179.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | $55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $84.00M derived: sum of 2 quarters · filed 2018-02-22 | $172.00M derived: sum of 3 quarters · filed 2018-02-22 | $224.00M 10-K · filed 2018-02-22 | |||
| 2017-10-01 | $29.00M 10-Q · filed 2017-11-09 | $117.00M derived: sum of 2 quarters · filed 2017-11-09 | $169.00M 10-Q · filed 2017-11-09 | $92.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-07-02 | $88.00M 10-Q · filed 2017-08-10 | $140.00M 10-Q · filed 2017-08-10 | $63.00M derived: sum of 3 quarters · filed 2018-05-10 | $31.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-04-02 | $52.00M 10-Q · filed 2018-05-10 | -$25.00M derived: sum of 2 quarters · filed 2018-05-10 | -$57.00M derived: sum of 3 quarters · filed 2018-05-10 | -$179.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | -$77.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$109.00M derived: sum of 2 quarters · filed 2018-02-22 | -$231.00M derived: sum of 3 quarters · filed 2018-02-22 | -$158.00M 10-K · filed 2018-02-22 | |||
| 2016-10-02 | -$32.00M 10-Q · filed 2017-11-09 | -$154.00M derived: sum of 2 quarters · filed 2017-11-09 | -$81.00M 10-Q · filed 2017-11-09 | -$143.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-07-03 | -$122.00M 10-Q · filed 2017-08-10 | -$49.00M 10-Q · filed 2017-08-10 | -$111.00M derived: sum of 3 quarters · filed 2018-02-22 | -$126.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-04-03 | $72.00M 10-Q · filed 2017-05-11 | $11.00M derived: sum of 2 quarters · filed 2018-02-22 | -$4.00M derived: sum of 3 quarters · filed 2018-02-22 | $151.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2015-12-31 | -$61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$76.00M derived: sum of 2 quarters · filed 2018-02-22 | $79.00M derived: sum of 3 quarters · filed 2018-02-22 | -$104.00M 10-K · filed 2018-02-22 | |||
| 2015-09-27 | -$15.00M 10-Q · filed 2016-11-10 | $140.00M derived: sum of 2 quarters · filed 2016-11-10 | -$43.00M 10-Q · filed 2016-11-10 | -$122.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-06-28 | $155.00M 10-Q · filed 2016-08-11 | -$28.00M 10-Q · filed 2016-08-11 | -$107.00M derived: sum of 3 quarters · filed 2017-02-23 | -$282.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-29 | -$183.00M 10-Q · filed 2016-05-12 | -$262.00M derived: sum of 2 quarters · filed 2017-02-23 | -$437.00M derived: sum of 3 quarters · filed 2017-02-23 | -$446.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | -$79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$254.00M derived: sum of 2 quarters · filed 2017-02-23 | -$263.00M derived: sum of 3 quarters · filed 2017-02-23 | -$262.00M 10-K · filed 2017-02-23 | |||
| 2014-09-28 | -$175.00M 10-Q · filed 2015-11-05 | -$184.00M derived: sum of 2 quarters · filed 2015-11-05 | -$183.00M 10-Q · filed 2015-11-05 | -$135.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-29 | -$9.00M 10-Q · filed 2015-08-06 | -$8.00M 10-Q · filed 2015-08-06 | $40.00M derived: sum of 3 quarters · filed 2016-02-29 | $156.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-30 | $1.00M 10-Q · filed 2015-05-07 | $49.00M derived: sum of 2 quarters · filed 2016-02-29 | $165.00M derived: sum of 3 quarters · filed 2016-02-29 | $254.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $164.00M derived: sum of 2 quarters · filed 2016-02-29 | $253.00M derived: sum of 3 quarters · filed 2016-02-29 | $63.00M 10-K · filed 2016-02-29 | |||
| 2013-09-29 | $116.00M 10-Q · filed 2014-11-06 | $132.00M 10-Q · filed 2013-11-08 | $205.00M derived: sum of 2 quarters · filed 2014-11-06 | $15.00M 10-Q · filed 2014-11-06 | $43.00M 10-Q · filed 2013-11-08 | $148.00M derived: sum of 4 quarters · filed 2015-02-27 | |
| 2013-06-30 | $89.00M 10-Q · filed 2014-08-07 | $55.00M 10-Q · filed 2013-08-09 | -$78.00M 10-Q · filed 2014-08-07 | -$89.00M 10-Q · filed 2013-08-09 | $32.00M derived: sum of 3 quarters · filed 2015-02-27 | $84.00M derived: sum of 4 quarters · filed 2015-02-27 | |
| 2013-03-31 | -$167.00M 10-Q · filed 2014-05-08 | -$57.00M derived: sum of 2 quarters · filed 2015-02-27 | -$5.00M derived: sum of 3 quarters · filed 2015-02-27 | -$138.00M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $110.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $162.00M derived: sum of 2 quarters · filed 2015-02-27 | $29.00M derived: sum of 3 quarters · filed 2015-02-27 | $144.00M 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $52.00M 10-Q · filed 2013-11-08 | -$81.00M derived: sum of 2 quarters · filed 2013-11-08 | $34.00M 10-Q · filed 2013-11-08 | ||||
| 2012-07-01 | -$133.00M 10-Q · filed 2013-08-09 | -$18.00M 10-Q · filed 2013-08-09 | |||||
| 2011-12-31 | -$135.00M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |